Takeda Halts Development Of Hypoglycemic Agent Fasiglifam After Safety Concerns
This article was originally published in PharmAsia News
Executive Summary
Takeda discontinued the development of one of its flagship products, the new oral hypoglycemic agent fasiglifam, after concerns emerged regarding the safety of the drug for the liver.